Antigen and cellular modulation approaches
| Approach | Impact on mAb tumor PK | mAb/tumor model | Source |
|---|---|---|---|
| pH sensitive mAb | 30% increase in tumor AUC (0–14 days) in comparison to non-pH sensitive mAb T84.66 | 10H6/T84.66 MC38CEA+ | 126 |
| Paclitaxel administered 2 days after mAb administration | 30% increase in cumulated activity 0–6 days | 111In-DOTA-Gly3Phe-m170/breast or prostate cancer | 106 |
| 5-fluorouracil treatment 2 days prior to mAb administration | 148% increase in uptake 5 days after administration | 125I-NHS76 Colon 26 | 107 |
| Paclitaxel treatment 2 days prior to mAb administration | 102% increase in uptake 5 days after administration | 125I-NHS76 Colon 26 | 107 |
| Tofacitinib | 48% increase (LMB) and 133% increase (BV421) in tumor cell uptake/binding 3 h after administration | LMB-100/KLM-1 BV421/MDA-MB-461 | 108 |
| Junction opener 1 | 500% increase in tumor uptake 12 h after administration | Trastuzumab HCC1954 | 109 |